Developer docs
API playgroundTry for free, no card

Search company profiles

Cerulean Pharma

Full company profile

uuid002w31j

Namestring
Cerulean Pharma
Legal namestring
Daré Bioscience, Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Daré Bioscience, Inc. (the operating successor to Cerulean Pharma following a July 2017 business combination) is a clinical-stage women's health biotech that develops differentiated therapeutics for conditions historically underserved by the medical establishment, including contraception, menopause, HPV infection, vaginal health, and female sexual health. The company's core technology is built around proprietary vaginal drug delivery systems, including soft gel vaginal inserts (DARE-HPV, a fixed-dose lopinavir/ritonavir formulation for persistent high-risk HPV), topical sildenafil cream (DARE to PLAY), hormone-free knitted-polymer contraceptive devices (Ovaprene), hormone-free vaginal inserts for postmenopausal sexual pain (DARE-VVA1), and clinically studied vaginal probiotic capsules (Flora Sync LF5, containing the proprietary Limosilactobacillus fermentum LF5 strain). The company operates a dual-path commercialization model: pursuing traditional FDA approval for pipeline assets while leveraging Section 503B compounding to accelerate patient access for products like DARE to PLAY.

Revenue mechanics are in early stages. Flora Sync LF5, launched in June 2026 at $49 per box of 6 capsules, is sold direct-to-consumer through the DARE Health Hub e-commerce platform and represents the company's first product revenue. DARE to PLAY is available via pre-fulfillment prescription in all 50 states through pharmacy networks. The company is listed on NASDAQ as DARE, is headquartered in San Diego, California, and has 1-10 employees. Government grants — including a $2.0 million NIH NIAID SBIR award and an up to $10 million ARPA-H contract for the DARE-HPV program — provide non-dilutive capital alongside equity funding. The Ovaprene pivotal Phase 3 study is conducted under a CRADA with NICHD. The company has 0 FDA-approved products and a portfolio of sub-brands (DARE to PLAY, DARE to RESTORE, DARE to RECLAIM, DARE to SUPPORT, DARE to PLAN, DARE to FIGHT) addressing the full life-stage continuum of women's health needs.

Short descriptiontext

Daré Bioscience is a clinical-stage women's health biotech that develops and commercializes proprietary vaginal drug-delivery therapeutics—including vaginal probiotics, topical sildenafil, and clinical-stage candidates for HPV, contraception, and menopause—serving women across all life stages.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
women's health therapeutics, vaginal drug delivery, clinical-stage biopharmaceuticals, hormone-free contraception, HPV antiviral treatment
Industry3 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Women's Health Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Prescription Drug Products
TypeOne Time License
Description

Prescription-based pharmaceutical products including DARE to PLAY sildenafil cream, which is available for pre-fulfillment prescriptions in all 50 states. Revenue generated through pharmacy fulfillment networks.

darebioscience.com
2Over-the-Counter Women's Health Products
TypeTransaction Fee
Description

Non-prescription consumer health products sold directly through the DARE Health Hub e-commerce platform, including Flora Sync LF5 vaginal probiotic capsules at $49 per box.

darebioscience.com
3Government Grants and Contracts
TypeSubscription Recurring
Description

Non-dilutive funding from NIH/NIAID grants ($2.0 million SBIR award for DARE-HPV) and ARPA-H contracts (up to $10 million for DARE-HPV Phase 2 study). Also includes NICHD CRADA for Ovaprene Phase 3 study.

darebioscience.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Pricing details1 tier
1Flora Sync LF5 Vaginal Probiotic - $49 per box
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Each box contains 6 vaginal capsules allowing for 2 courses (3 capsules/course) of vaginal microbiome balance support. Available through DARE Health Hub with no prescription required. Limited-time launch offer of 30% off + free shipping.

darebioscience.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1DARE to PLAY
Description

First-of-its-kind topical female arousal cream with sildenafil for sexual health.

darebioscience.com
+7 more records
Core offering1 text field

Cerulean Pharma (now operating as Daré Bioscience, Inc.) develops and commercializes targeted therapeutics for women's health, including a compounded topical sildenafil cream (DARE to PLAY) and a vaginal probiotic capsule (Flora Sync LF5) sold through direct-to-consumer and pharmacy channels. The company is also advancing clinical-stage drug and drug/device candidates such as DARE-HPV (a soft gel vaginal insert for high-risk HPV) and Ovaprene (a hormone-free monthly contraceptive). It operates a dual-path model combining FDA approval pursuits with Section 503B compounding to accelerate patient access.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 96% of women achieved vaginal microbiome balance within 3 days; 90% maintained balance at 2 weeks (Flora Sync LF5 clinical trial, Frontiers in Microbiology 2024)
+2 more records
Product overview1 text field

Daré Bioscience (formerly Cerulean Pharma) is a purpose-driven health biotech company focused on women's health. The company operates a dual-path model—pursuing FDA approval pathways while leveraging Section 503B compounding—to accelerate access to differentiated therapies. The product portfolio spans consumer products (DARE to PLAY™ sildenafil cream, Flora Sync LF5™ vaginal probiotics) and an innovation pipeline including DARE-HPV (antiviral vaginal insert for HPV), Ovaprene® (hormone-free monthly contraceptive), DARE-VVA1 (vaginal insert for sexual pain), and multiple sub-brands under DARE to RESTORE™, DARE to RECLAIM™, DARE to SUPPORT™, DARE to PLAN™, and DARE to FIGHT™ covering contraception, menopause, vaginal health, pregnancy support, and infectious disease.

Product and service5 records
1DARE to PLAY Sildenafil Cream
CategoryPrescription consumer health product
Description

First-of-its-kind topical female arousal cream containing 3.6% sildenafil, manufactured in a 503B outsourcing facility under pharmaceutical cGMP and available by prescription in all 50 U.S. states.

2Flora Sync LF5 Vaginal Probiotic
CategoryOver-the-counter consumer health product
Description

Vaginal probiotic capsules containing Limosilactobacillus fermentum LF5, a strain isolated from the vaginal microbiome of healthy women, designed to restore microbiome balance and support vaginal comfort. Available without prescription at $49 per box (6 capsules).

3DARE-HPV
CategoryInvestigational drug (Phase 2 pipeline)
Description

Investigational proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, in development as a non-surgical, localized, self-administered treatment for persistent high-risk HPV infection. Currently in Phase 2 clinical study.

4Ovaprene
CategoryInvestigational drug/device (Phase 3 pipeline)
Description

Investigational hormone-free monthly intravaginal contraceptive that combines a locally acting non-hormonal agent impeding sperm motility with a unique knitted polymer barrier that physically blocks sperm from entering the cervical canal. Currently in pivotal Phase 3 study.

5DARE-VVA1
CategoryInvestigational drug (pipeline)
Description

Investigational hormone-free vaginal insert for sexual pain post-menopause or following breast cancer treatment.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

Cooperative Research and Development Agreement (CRADA) with NICHD/NIH for the pivotal Phase 3 study of Ovaprene. The agreement leverages NICHD's contraceptive clinical trial expertise while sharing costs of the Phase 3 pivotal study.

2Probiotical
Strategic tierCoreTypeTechnology or Integration
Description

Italian probiotic company (founded 1985, with family legacy in lactic acid bacteria research dating back to 1920s) manufactures Flora Sync LF5 under current Good Manufacturing Practices (cGMP). Probiotical represents Daré's manufacturing partner for the vaginal probiotic product with expertise in evidence-based probiotic science, strain selection, and quality standards.

darebioscience.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage women's health company focused on contraceptive products. Directly comparable as a small-cap public peer pursuing FDA approval in non-hormonal and hormonal contraception, overlapping with Daré's Ovaprene program.

TypeDirect peer
Description

Develops women's health and prostate cancer therapies, with approved products in heavy menstrual bleeding and endometriosis. Comparable as a focused women's health commercial-stage peer that grew via differentiated therapeutic approvals.

TypeBroad incumbent
Description

Large-cap women's health diagnostics and medical device company with significant HPV/cervical health franchise. Comparable at the category level (HPV, women's diagnostics) and represents a potential strategic acquirer of Daré's DARE-HPV asset.

TypeDirect peer
Description

Women's health-focused branded pharmaceutical company marketing prescription products in menopause, contraception, and vaginal health. Highly comparable business model to Daré's portfolio across DARE to RECLAIM and DARE to PLAN.

TypeBroad incumbent
Description

Spun off from Merck as a global women's health incumbent with established franchises in contraception, fertility, and menopause. Provides a scaled comparator for Daré's pipeline ambitions across multiple women's health categories.

TypeDirect peer
Description

Private/specialty pharmaceutical company with women's health portfolio including vaginal and reproductive health products. Comparable as a niche women's health commercial operator and a potential strategic acquirer for Daré assets.

TypeDirect peer
Description

Biopharmaceutical company focused on women's health (including sexual health) and oncology. Comparable to Daré's women's health focus and to DARE to PLAY's positioning in female sexual health.

TypeBroad incumbent
Description

Global incumbent in women's health with leading contraceptive and menopause franchises (Mirena, Yaz, etc.). Represents the dominant established competitor in the same prescription categories where Daré is launching.

TypeDirect peer
Description

Belgian women's health company developing novel contraceptives and hormone therapy products. Comparable business model with differentiated women's health pipeline including non-hormonal contraception similar to Ovaprene.

TypeDirect peer
Description

Women's health company commercializing hormone-free contraceptives and vaginal health products. Comparable in product type (vaginal pH regulator vs. Daré's vaginal probiotic and non-hormonal contraceptive) and target customer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cerulean Pharma

Women's Health Pharmaceuticalsdarebioscience.com

Daré Bioscience is a clinical-stage women's health biotech that develops and commercializes proprietary vaginal drug-delivery therapeutics—including vaginal probiotics, topical sildenafil, and clinical-stage candidates for HPV, contraception, and menopause—serving women across all life stages.

What Cerulean Pharma does

Daré Bioscience, Inc. (the operating successor to Cerulean Pharma following a July 2017 business combination) is a clinical-stage women's health biotech that develops differentiated therapeutics for conditions historically underserved by the medical establishment, including contraception, menopause, HPV infection, vaginal health, and female sexual health. The company's core technology is built around proprietary vaginal drug delivery systems, including soft gel vaginal inserts (DARE-HPV, a fixed-dose lopinavir/ritonavir formulation for persistent high-risk HPV), topical sildenafil cream (DARE to PLAY), hormone-free knitted-polymer contraceptive devices (Ovaprene), hormone-free vaginal inserts for postmenopausal sexual pain (DARE-VVA1), and clinically studied vaginal probiotic capsules (Flora Sync LF5, containing the proprietary Limosilactobacillus fermentum LF5 strain). The company operates a dual-path commercialization model: pursuing traditional FDA approval for pipeline assets while leveraging Section 503B compounding to accelerate patient access for products like DARE to PLAY.

Revenue mechanics are in early stages. Flora Sync LF5, launched in June 2026 at $49 per box of 6 capsules, is sold direct-to-consumer through the DARE Health Hub e-commerce platform and represents the company's first product revenue. DARE to PLAY is available via pre-fulfillment prescription in all 50 states through pharmacy networks. The company is listed on NASDAQ as DARE, is headquartered in San Diego, California, and has 1-10 employees. Government grants — including a $2.0 million NIH NIAID SBIR award and an up to $10 million ARPA-H contract for the DARE-HPV program — provide non-dilutive capital alongside equity funding. The Ovaprene pivotal Phase 3 study is conducted under a CRADA with NICHD. The company has 0 FDA-approved products and a portfolio of sub-brands (DARE to PLAY, DARE to RESTORE, DARE to RECLAIM, DARE to SUPPORT, DARE to PLAN, DARE to FIGHT) addressing the full life-stage continuum of women's health needs.

Cerulean Pharma firmographics

Firmographics
Name
Cerulean Pharma
Legal name
Daré Bioscience, Inc.
Website
https://darebioscience.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Daré Bioscience is a clinical-stage women's health biotech that develops and commercializes proprietary vaginal drug-delivery therapeutics—including vaginal probiotics, topical sildenafil, and clinical-stage candidates for HPV, contraception, and menopause—serving women across all life stages.
Ownership category
akta.pro rank

Cerulean Pharma industry classification

Industry
Product category
Women's Health Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services

Keywords

  • Women's health therapeutics
  • Vaginal drug delivery
  • Clinical-stage biopharmaceuticals
  • Hormone-free contraception
  • HPV antiviral treatment

Where Cerulean Pharma is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cerulean Pharma business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Prescription Drug Products: Prescription-based pharmaceutical products including DARE to PLAY sildenafil cream, which is available for pre-fulfillment prescriptions in all 50 states. Revenue generated through pharmacy fulfillment networks.
  2. Over-the-Counter Women's Health Products: Non-prescription consumer health products sold directly through the DARE Health Hub e-commerce platform, including Flora Sync LF5 vaginal probiotic capsules at $49 per box.
  3. Government Grants and Contracts: Non-dilutive funding from NIH/NIAID grants ($2.0 million SBIR award for DARE-HPV) and ARPA-H contracts (up to $10 million for DARE-HPV Phase 2 study). Also includes NICHD CRADA for Ovaprene Phase 3 study.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goFlora Sync LF5 Vaginal Probiotic - $49 per box

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Cerulean Pharma product offering

Product offering

Core offering

Cerulean Pharma (now operating as Daré Bioscience, Inc.) develops and commercializes targeted therapeutics for women's health, including a compounded topical sildenafil cream (DARE to PLAY) and a vaginal probiotic capsule (Flora Sync LF5) sold through direct-to-consumer and pharmacy channels. The company is also advancing clinical-stage drug and drug/device candidates such as DARE-HPV (a soft gel vaginal insert for high-risk HPV) and Ovaprene (a hormone-free monthly contraceptive). It operates a dual-path model combining FDA approval pursuits with Section 503B compounding to accelerate patient access.

Product overview

Daré Bioscience (formerly Cerulean Pharma) is a purpose-driven health biotech company focused on women's health. The company operates a dual-path model—pursuing FDA approval pathways while leveraging Section 503B compounding—to accelerate access to differentiated therapies. The product portfolio spans consumer products (DARE to PLAY™ sildenafil cream, Flora Sync LF5™ vaginal probiotics) and an innovation pipeline including DARE-HPV (antiviral vaginal insert for HPV), Ovaprene® (hormone-free monthly contraceptive), DARE-VVA1 (vaginal insert for sexual pain), and multiple sub-brands under DARE to RESTORE™, DARE to RECLAIM™, DARE to SUPPORT™, DARE to PLAN™, and DARE to FIGHT™ covering contraception, menopause, vaginal health, pregnancy support, and infectious disease.

Differentiator

Problem solved

Functional benefit

Brands

  • DARE to PLAY: First-of-its-kind topical female arousal cream with sildenafil for sexual health.
  • DARE to RESTORE
  • DARE to RECLAIM
  • DARE to SUPPORT
  • DARE to PLANTM
  • DARE to FIGHTTM
  • Flora Sync LF5
  • DARE Health Hub

Products and services

  • DARE to PLAY Sildenafil Cream First-of-its-kind topical female arousal cream containing 3.6% sildenafil, manufactured in a 503B outsourcing facility under pharmaceutical cGMP and available by prescription in all 50 U.S. states.
  • Flora Sync LF5 Vaginal Probiotic Vaginal probiotic capsules containing Limosilactobacillus fermentum LF5, a strain isolated from the vaginal microbiome of healthy women, designed to restore microbiome balance and support vaginal comfort. Available without prescription at $49 per box (6 capsules).
  • DARE-HPV Investigational proprietary fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert, in development as a non-surgical, localized, self-administered treatment for persistent high-risk HPV infection. Currently in Phase 2 clinical study.
  • Ovaprene Investigational hormone-free monthly intravaginal contraceptive that combines a locally acting non-hormonal agent impeding sperm motility with a unique knitted polymer barrier that physically blocks sperm from entering the cervical canal. Currently in pivotal Phase 3 study.
  • DARE-VVA1 Investigational hormone-free vaginal insert for sexual pain post-menopause or following breast cancer treatment.

Quantifiable outcome

  • 96% of women achieved vaginal microbiome balance within 3 days; 90% maintained balance at 2 weeks (Flora Sync LF5 clinical trial, Frontiers in Microbiology 2024)
  • +2 more outcomes

Companies that use Cerulean Pharma

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Cerulean Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cerulean Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)coreStrategic or Co-development Partner · 1 July 2021Cooperative Research and Development Agreement (CRADA) with NICHD/NIH for the pivotal Phase 3 study of Ovaprene. The agreement leverages NICHD's contraceptive clinical trial expertise while sharing costs of the Phase 3 pivotal study.
  • ProbioticalcoreTechnology or IntegrationItalian probiotic company (founded 1985, with family legacy in lactic acid bacteria research dating back to 1920s) manufactures Flora Sync LF5 under current Good Manufacturing Practices (cGMP). Probiotical represents Daré's manufacturing partner for the vaginal probiotic product with expertise in evidence-based probiotic science, strain selection, and quality standards.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Cerulean Pharma competitors and assessment

Company assessment

Direct peers

  • Agile Therapeutics: Clinical-stage women's health company focused on contraceptive products. Directly comparable as a small-cap public peer pursuing FDA approval in non-hormonal and hormonal contraception, overlapping with Daré's Ovaprene program.
  • Myovant Sciences: Develops women's health and prostate cancer therapies, with approved products in heavy menstrual bleeding and endometriosis. Comparable as a focused women's health commercial-stage peer that grew via differentiated therapeutic approvals.
  • TherapeuticsMD: Women's health-focused branded pharmaceutical company marketing prescription products in menopause, contraception, and vaginal health. Highly comparable business model to Daré's portfolio across DARE to RECLAIM and DARE to PLAN.
  • Sebela Pharmaceuticals: Private/specialty pharmaceutical company with women's health portfolio including vaginal and reproductive health products. Comparable as a niche women's health commercial operator and a potential strategic acquirer for Daré assets.
  • Veru Inc. Biopharmaceutical company focused on women's health (including sexual health) and oncology. Comparable to Daré's women's health focus and to DARE to PLAY's positioning in female sexual health.
  • Mithra Pharmaceuticals: Belgian women's health company developing novel contraceptives and hormone therapy products. Comparable business model with differentiated women's health pipeline including non-hormonal contraception similar to Ovaprene.
  • Evofem Biosciences: Women's health company commercializing hormone-free contraceptives and vaginal health products. Comparable in product type (vaginal pH regulator vs. Daré's vaginal probiotic and non-hormonal contraceptive) and target customer.

Broad incumbents

  • Hologic: Large-cap women's health diagnostics and medical device company with significant HPV/cervical health franchise. Comparable at the category level (HPV, women's diagnostics) and represents a potential strategic acquirer of Daré's DARE-HPV asset.
  • Organon & Co. Spun off from Merck as a global women's health incumbent with established franchises in contraception, fertility, and menopause. Provides a scaled comparator for Daré's pipeline ambitions across multiple women's health categories.
  • Bayer (Women's Healthcare): Global incumbent in women's health with leading contraceptive and menopause franchises (Mirena, Yaz, etc.). Represents the dominant established competitor in the same prescription categories where Daré is launching.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cerulean Pharma social profiles

Digital presence

Cerulean Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cerulean Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Cerulean Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cerulean Pharma funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cerulean Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cerulean Pharma

What does Cerulean Pharma do?

Cerulean Pharma (now operating as Daré Bioscience, Inc.) develops and commercializes targeted therapeutics for women's health, including a compounded topical sildenafil cream (DARE to PLAY) and a vaginal probiotic capsule (Flora Sync LF5) sold through direct-to-consumer and pharmacy channels. The company is also advancing clinical-stage drug and drug/device candidates such as DARE-HPV (a soft gel vaginal insert for high-risk HPV) and Ovaprene (a hormone-free monthly contraceptive). It operates a dual-path model combining FDA approval pursuits with Section 503B compounding to accelerate patient access.

Is Cerulean Pharma a public or private company?

Cerulean Pharma is a public company. It is classified as public and is currently operating.

When was Cerulean Pharma founded?

Cerulean Pharma was founded in 2015. It employs 11 to 50 people.

Where is Cerulean Pharma based?

Cerulean Pharma is headquartered in San Diego, United States, in the North America region.

How does Cerulean Pharma make money?

Three revenue lines are on record. Prescription Drug Products are the primary driver. The others are over-the-Counter Women's Health Products and government Grants and Contracts.

Who are Cerulean Pharma's main competitors?

Direct peers on record are Agile Therapeutics, Myovant Sciences, TherapeuticsMD, Sebela Pharmaceuticals, Veru Inc., Mithra Pharmaceuticals and Evofem Biosciences. Broad incumbents are Hologic, Organon & Co. and Bayer (Women's Healthcare).

Does Cerulean Pharma have an API?

No public API is recorded for Cerulean Pharma.

What industry is Cerulean Pharma in?

Cerulean Pharma's product category is Women's Health Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DDare Bioscience, Inc. has filed a notice of exempt offering of securities with the SEC, including a total offering amount of $3,544,992. The offering is linked to a business combination transaction involving shares of common stock issued to former stockholders of a company acquired by Dare Bioscience.FierceBiotechCerulean Pharma Inc. (CERU) Appoints David R. Walt, Ph.D. To Board Of DirectorsCerulean Pharma appointed David R. Walt, Ph.D., to its board of directors, effective September 23, 2015. The company's nanoparticle-drug conjugate CRLX101 is in Phase 2 clinical development, and CRLX301 is in Phase 1/2a. Walt will help expand the pipeline of platform-generated NDCs.PR NewswireBiotech Influence in Exploding Cannabis Industry Boosting Innovative Treatments and TherapiesBiotech companies are increasingly participating in the medicinal cannabis industry, with Earth Science Tech appointing new management for its MSN-2 medical device project and announcing international marketing consultants. Concurrently, Zynerba Pharmaceuticals, CV Sciences, Medical Marijuana Inc., and Cerulean Pharma reported recent stock performance gains and operational updates regarding their respective cannabinoid and biotech initiatives.PR NewswireResearch Reports Coverage on Biotech Stocks -- Cerulean Pharma, AveXis, TG Therapeutics, and Aralez PharmaStock Callers initiated research coverage on four biotech stocks on February 8, 2017: Cerulean Pharma (down 4.13%), AveXis (down 2.71%), TG Therapeutics (down 1.02%), and Aralez Pharma (down 1.19%), with each company receiving brief stock performance metrics and business descriptions. Cerulean Pharma's shares have rallied 41.46% in the last month despite Tuesday's decline, while Aralez Pharma's shares have gained 8.09% over three months. The article promotes free research reports available through Stock Callers' website for each of the covered stocks.PR NewswireBiotech Stocks on Investors' Radar -- Advaxis, Cerus, Kite Pharma, and Cerulean PharmaOn October 26, 2016, Stock-Callers.com reviewed four biotech stocks listed on NASDAQ, with all four companies' shares declining that day. Advaxis Inc. fell 1.90% to $8.24, Cerus Corporation dropped 4.02% to $5.01, Kite Pharma Inc. decreased 0.74% to $45.68, and Cerulean Pharma Inc. slipped 1.71% to $0.86. The article provides technical analysis metrics including trading volumes, moving averages, and RSI readings for each company.GlobeNewswireCerulean Pharma to Present at JMP Securities Healthcare ConferenceCerulean Pharma announced that Christopher D. T. Guiffre, Senior Vice President and Chief Business Officer, will present at the JMP Securities Healthcare Conference in New York City on June 24, 2014, at 3:30 p.m. ET. A live webcast will be available on the company's website, with a replay for two weeks.VC News DailyCerulean Pharma Closes $15M Series DCerulean Pharma announced the closing of a $15 million Series D financing round with participation from new investor CVF and existing investors Polaris, Venrock, Lilly Ventures, Lux Capital, and Bessemer Venture Partners. The funding will support a randomized Phase 2 trial of CRLX101 in non-small cell lung cancer and advance a docetaxel nanopharmaceutical candidate into clinical trials, while also pursuing platform expansion including RNA-based therapeutics delivery. Robert Paull, co-founder and managing partner at Lux Capital, has joined Cerulean's board of directors in conjunction with this financing.